Eli Lilly Phase 2 data showed eloratzp delivered up to 54.1 pounds of average weight loss
LLY•Phase 2 data showed eloratzp delivered average weight loss of up to 54.1 pounds, or 23.3%, at 48 weeks in adults with obesity and type 2 diabetes. It lowered A1C by up to 2.9%; separate Phase 3 data showed Zepbound reduced BMI by an average of 21.4% in adolescents with obesity.
1. Trial results
Eli Lilly said Phase 2 data showed eloratzp delivered average weight loss of up to 54.1 pounds, or 23.3%, at 48 weeks in adults with obesity and type 2 diabetes. A1C fell by up to 2.9%, with up to 77% of participants achieving normal blood sugar levels. In Phase 3, Zepbound reduced BMI by an average of 21.4% in adolescents aged 12 to under 18 with obesity.
